Ultra-processed food consumption and the risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Menée auprès de 98 265 participants à l'essai "the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial" (durée moyenne de suivi : 8,86 ans), cette étude analyse l'association entre une consommation d'aliments ultra-transformés et le risque de cancer du pancréas (387 cas)
Whether ultra-processed food consumption is associated with the risk of pancreatic cancer has not been determined. We performed a prospective study to fill this gap. A population-based cohort of 98265 American adults was identified from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Ultra-processed foods were defined by the NOVA classification. Cox regression was used to estimate hazard ratios (HRs) for pancreatic cancer incidence. Subgroup analysis was performed to identify the potential effect modifiers. During a mean follow-up of 8.86 years, 387 pancreatic cancer cases occurred. High consumption of ultra-processed foods was found to be associated with an increased risk of pancreatic cancer [fully adjusted HRquartile4 vs. 1: 1.49; 95% confidence interval (CI): 1.07, 2.07; Ptrend=0.021] in a linear dose–response manner (Pnonlinearity=0.075). Subgroup analysis further found that the positive association of ultra-processed food consumption with the risk of pancreatic cancer was more pronounced in subjects aged <65 years (HRquartile4 vs. 1: 2.17; 95% CI: 1.14, 4.15) than in those with aged ≥65 years (HRquartile4 vs. 1: 1.32; 95% CI: 0.88, 1.94), though the interaction test failed to achieve the statistical significance (Pinteraction=0.061). These findings suggest that reducing ultra-processed food consumption may be beneficial in decreasing pancreatic cancer incidence.